We investigated the effects of 4-17 month supplementation with v-3 fatty acids and antioxidants (Smartfish drink; Smartfish AS, Oslo, Norway) in 12 patients with minor cognitive impairment (MCI) [minimental state examination (MMSE) ‡19], 2 patient with pre-MCI s (normal MMSE), and 7 patients with Alzheimer disease (AD) (MMSE <19). We measured the phagocytosis of amyloid-b 1-42 (Ab) by flow cytometry and microscopy, the transcription of inflammatory genes by RT-PCR, the production of resolvin D1 (RvD1) by enzyme immunoassay, and the cognitive status by MMSE. In patients with MCI and pre-MCI, phagocytosis of Ab by monocytes increased from 530 to 1306 mean fluorescence intensity units (P = 0.016). The increase in patients with AD was not significant (N.S.). The lipidic mediator RvD1, which stimulates Ab phagocytosis in vitro, increased in macrophages in 80% of patients with MCI and pre-MCI (mean increase 9.95 pg/ml) (N.S.). Transcription of inflammatory genes' mRNAs was increased in a subgroup of patients with low transcription at baseline, whereas it was not significantly changed in patients with high transcription at baseline. The mean MMSE score of patients with MCI and pre-MCI was 25.9 at baseline and 25.7 after 4-17 months (N.S.). Our study is the first to show significant immune and biochemical effects of v-3 fatty acids with antioxidants in patients with MCI. Cognitive benefits of v-3 supplementation in patients with MCI should be tested in a clinical trial.-Fiala, M., Halder, R. C., Sagong, B., Ross, O., Sayre, J., Porter, V., Bredesen, D. E. v-3 supplementation increases amyloid-b phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J. 29, 000-000 (2015). www.fasebj.org
INTRODUCTION
BRAIN CLEARANCE OF THE neurotoxic molecule amyloid-b 1-42 (Ab) (1) , either by Ab antibodies or g-secretase inhibitors and modulators, has been a cornerstone of experimental Alzheimer disease (AD) therapeutics. The antibodies and inhibitors have failed to achieve significant clinical effects (2) . Monocytes/macrophages of patients with AD have a defect in phagocytosis and degradation of Ab (3) . Intriguingly, in vitro the v-3 fatty acid docosahexaenoic acid (DHA) and the "specialized proresolving mediator" (SPM) resolvin D1 (RvD1) partially recovered phagocytosis of Ab by AD monocytes/macrophages (4) .
Recent results suggest that the pathophysiology of AD is highly complex, involving fundamentally impaired connectivity of the signaling network related to the neuroprotective sirtuin 1:neurotoxic sirtuin 2, and increased t phosphorylation (5) . Nevertheless, inflammation appears a crucial mechanism in AD because strong accumulation of Ab in the cortex but without signs of inflammation is found in some nondemented individuals (6) .
We have tested the effects of v-3 on inflammation and Ab phagocytosis in peripheral blood mononuclear cells (PBMCs) of patients with AD. Amyloid precursor protein transgenic mice are poor models for testing immune therapies because mice lack correlation with inflammatory responses in humans (7) , neurotoxicity of Ab differs in mice and men (8) , and mice do not have the genetic variability in human leukocyte antigen complex genes and TLRs observed in patients (9) . The inflammatory activation in PBMCs of patients with AD is variable, schematically either up-regulated or down-regulated in comparison to control subjects (4) . In addition, monocytes/macrophages of nearly all patients with AD do not efficiently phagocytize and degrade Ab (3, 10) . SPMs from v-3 are known to terminate acute inflammation, increase phagocytosis, and have distinct roles in attenuating chronic inflammation (11) and, thus, appear suitable for repairing defective Ab Abbreviations: Ab, amyloid-b 1-42; AD, Alzheimer disease; ApoE3, apolipoprotein E3; ApoE4, apolipoprotein E4; DHA, docosahexaenoic acid; EIA, enzyme immunoassay; EPA, eicosapentaenoic acid; FACS, fluorescent activated cell sorting; IMDM, Iscove's modified Dulbecco's medium; MCI, minor cognitive impairment; MFI, mean fluorescence intensity;
(continued on next page) phagocytosis and regulating inflammation in patients with AD. Interestingly, the AD brain was found to have defective SPMs in the hippocampus (12) . Although v-3s are a popular nutritional supplement against AD, their effects on innate immunity have not been studied in patients with AD. The objective of this study has been to evaluate immune and pro-and anti-inflammatory effects of nutritional supplementation by v-3 and other components in the Smartfish drink (Smartfish AS, Oslo, Norway). This drink combines v-3 with natural antioxidants, resveratrol (for stimulation of sirtuin) (5), and vitamin D3 (for immune actions (4)), thus targeting several facets of AD pathogenesis (13) .
MATERIALS AND METHODS

Study design
This design was an open study of phagocytosis and gene transcription in PBMCs of patients with AD and minor cognitive impairment (MCI). The patients who requested v-3 supplementation received the Smartfish drink with v-3 and antioxidants. The patients were followed in 1-3 monthly intervals by testing Ab phagocytosis, RvD1 and minimental state examination (MMSE), and inflammatory gene transcription.
Study population
All subjects signed the Informed Consent of the immune study approved by the University of California, Los Angeles, institutional review board. Of the subjects, 84% requested v-3 (Smartfish) supplementation. The patient population included 1) v-3-supplemented patients with MMSE $19, of which 12 were patients with MCI and 2 pre-MCI ( Table 1) ; 2) 6 v-3-supplemented patients with AD with MMSE ,19 (Table 2); 3) 3 nonsupplemented patients with AD ( Table 3) ; and 4) 6 nonsupplemented cognitively normal subjects ( Table 4 ). The diagnoses were established by accepted criteria for AD (14) and MCI (15) and cognitive testing by MMSE. Defects in attention and calculation were found in 11 of 12 patients with MCI, defects in immediate recall in 7 of 12 patients, and defects in orientation in 4 patients. Patients with pre-MCI were those with subjective memory complaints without any pathology in the MMSE.
v-3 Drink with antioxidants
The subjects received daily supplementation with the Smartfish drink (200 ml) containing 1000 mg DHA, 1000 mg eicosapentaenoic acid (EPA), botanical antioxidants (pomegranate and chokeberry), 10 mg vitamin D3 and resveratrol (natureidentical form of transresveratrol), and other ingredients (whey protein, fiber, and fruit juice). For in vitro testing, Smartfish emulsion was diluted in fetal calf serum, sonicated, and then diluted in Iscove's modified Dulbecco's medium (IMDM) to the final concentration of 27 mg/ml DHA.
Isolation of PBMCs and macrophage cultures
Heparinized blood from the patients with AD was diluted with PBS (1:1 ratio; vol/vol). PBMCs were isolated from the diluted blood by the ficoll-hypaque gradient method at 2500 rpm for 20 minutes at room temperature, the mononuclear fraction was collected and washed 2 times with PBS, and cells were resuspended with IMDM. Macrophages were cultured from 50,000 mononuclear cells in IMDM with 10% autologous serum for 10-14 days in 8-well culture slides (Becton Dickinson Discovery Labware, Bedford, MA, USA).
Flow cytometric FAM-Ab phagocytosis assay
A total of 0.5 3 10 6 PBMCs were suspended in IMDM with 10% autologous serum and were incubated with or without 2 mg/ml FAM-Ab (AnaSpec, Fremont, CA, USA) overnight at 37°C in a 5% CO 2 incubator. The cells were washed 2 times with a fluorescent activated cell-sorting (FACS) buffer and then labeled for 30 minutes at 4°C with anti-CD14 PE (BD Biosciences/Pharmingen, San Diego, CA, USA). After incubation, cells were washed 2 times with FACS buffer and fixed with 1% paraformaldehyde. Flow cytometry was performed on FACSCalibur (Becton Dickinson, San Diego, CA, USA). The data were analyzed using FlowJo software (Ashland, OR, USA) with monocyte gate, based on forward and side scatter, and expressed in mean fluorescence intensity (MFI) units.
Fluorescent microscopic FAM-Ab phagocytosis assay
FAM-Ab (3 mg/ml) was added to macrophages in culture slides in IMDM and incubated overnight. Cells were washed, fixed, stained with phalloidin-tetramethylrhodamine (Sigma-Aldrich, St. Louis, MO, USA), and examined by fluorescence microscopy for FAM-Ab.
RvD1 enzyme immunoassay
Macrophages were harvested into ice-cold methanol and stored at 280°C. RvD1 was measured by the RvD1 EIA Kit according to the manufacturer's protocol (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, after drying methanol by vacuum centrifugation, enzyme immunoassay (EIA) buffer was added to control wells and the samples. The samples and 8 RvD1 standards were added in duplicate into the precoated RvD1 EIA plate. RvD1 tracer linked to acetylcholinesterase (50 ml) was added to all wells except the total activity and blank wells. Then, RvD1 EIA antiserum (50 ml) was added to all wells, except the total activity, the nonspecific binding, and the blank wells. The plate was incubated for 18 hours at 4°C and rinsed 5 times with wash buffer; 200 ml Ellman's reagent was then added to each well, and 5 ml tracer was added to the total activity wells. The plate was covered with plastic film, developed at 90-120 minutes in the dark with shaker, and read at 405 nm. After calculating the standard curve %B/B o (y) versus ln RvD1 (picograms per milliliter) (x), the concentration of RvD1 (x) was determined from the equation lnx = (103.6 2 y)/13.32.
mRNA transcriptional testing
The transcription of 48 inflammatory genes in 3 3 10 6 PBMCs was tested by RT-PCR as described (4) . RNA was extracted, and cDNA was prepared and mixed with the RT-PCR reagent SYBR Green Master Mix (Qiagen, Germantown, MD, USA) and added to a custom array with inflammatory genes according to the manufacturer's protocols.
(continued from previous page) MMSE, minimental state examination; N.S., not significant; PBMC, peripheral blood mononuclear cell; RvD1, resolvin D1; SPM, specialized proresolving mediator
Statistical analysis
Data were analyzed by a repeated measures ANOVA with Bonferroni adjustment for multiple comparisons and Hotelling's trace as the multivariate test.
RESULTS
v-3 Supplementation enhanced Ab phagocytosis by monocytes and macrophages and increased RvD1
We tested phagocytosis of Ab by monocytes using the flow cytometric test (Tables 1, 2, 3, and 4) . The MFI range in cognitively active subjects was previously established as .450 MFI units, and in patients with MCI and AD as #450 (3). Most patients with AD and MCI (except patients with MCI, no. 10-14, and patients with AD, no. 19 and 20, who had taken over-the-counter v-3 supplements before the first visit) had baseline tests satisfying these criteria. In patients with MCI and pre-MCI (MMSE $19), the mean MFI score on the first visit was 530.6 MFI units, and in patients with AD (MMSE ,19), it was 491.7 U; in the neversupplemented subgroup of patients with AD, it was 263.3 U, and in cognitively active control subjects, it was 1668.2 U. After v-3 supplementation, the MFI score increased in patients with MCI and pre-MCI to 944.3 U (P = 0.019) on the second visit and 1028.5 U on the third visit (P = 0.016), and in patients with AD to 695.0 on the second visit and (Fig. 1 and Table 1 ). The immune (MFI) response in some patients showed a delay or attenuation possibly related to various events, such as prostatitis in patient #2, diverticulitis in #4, travel without the drink in #12, and cancer in #13 (Fig. 1) . Nonsupplemented patients with AD maintained low MFI scores (,477 U), and control subjects maintained excellent scores (.1500 U). Remarkably, a cognitively normal (still playing bingo) 108-year-old woman had an excellent Ab phagocytosis score.
In addition, we evaluated phagocytosis of Ab by macrophages using fluorescence microscopy in 4 patients with MCI and 1 patient with AD. On nutritional supplementation (starting after visit 1), phagocytosis increased at visits 2 and 3 (Fig. 2) .
RvD1 production in macrophages was tested by EIA in 7 patients with MCI and pre-MCI (Fig. 1) . RvD1 increased on supplementation by an average of 9.95 pg/ml in 8 (80%) of these 10 patients with a caveat: in patient #2, RvD1 production was inhibited in parallel with prostatitis; in #4, in parallel with diverticulitis. In apolipoprotein E3 (ApoE3)/ ApoE4 patient #9, MMSE, MFI, and RvD1 plummeted after a vigorous initial response.
v-3 Supplementation stabilized MMSE in patients with MCI and pre-MCI
We tested cognition by the MMSE in all patients ( Fig. 3 and Table 1 ). The mean MMSE scores of patients with MCI and pre-MCI were 25.9 before supplementation (visit 1), 26.9 after 1-2.6 months of supplementation (visit 2), and 25.7 after 2.1-5.5 months of supplementation (visit 3; 3 patients were lost to follow-up) (N.S.). There were 3 patients with MCI followed for .1 year: patient #1 gained 4 points but lost 5 points on the last visit, patient #2 lost 1 point, and patient #3 lost 2 points (Table 1) . No effect on cognition was observed in patients with AD ( Fig. 3 and Table 2 ).
v-3 Supplementation regulated the transcription of inflammatory genes toward physiologic level As previously described (4), the baseline transcription of inflammatory genes is down-regulated in the "noninflammatory" group of patients with AD, and it is upregulated in the "inflammatory" group in comparison to controls. We tested inflammatory gene transcription in 9 patients on nutritional supplementation ( Table 5) . On follow-up visits after the start of supplementation, the transcription of IL-1b, IL-6, IL-8, C3, CCL2, CCL7, CCL8, and several CXCL chemokines was progressively increased in the noninflammatory patients with MCI, whereas in the inflammatory patients, the inflammatory transcription was not significantly changed.
DISCUSSION
Innate immunity in patients with AD is characteristic for defective Ab phagocytosis by macrophages and monocytes (3) and abnormal inflammatory activation of PBMCs (4). Here, we tested the in vivo effects of v-3 on Ab phagocytosis because of the well-known attenuation of inflammation and enhancement of phagocytosis by SPMs derived from v-3 (16). Enhancement of phagocytosis was previously shown in vitro with RvD1 (4). Nutritional supplementation by v-3 and antioxidants strongly enhanced Ab phagocytosis by monocytes and macrophages, particularly in patients with MCI and pre-MCI, and regulated abnormal inflammation toward control level. In patients with MCI and pre-MCI, Ab phagocytosis significantly increased already at the second visit 1-2 months after the start of supplementation, although the improvement was interrupted in some patients by intercurrent infections or surgeries. In parallel with the increase in Ab phagocytosis, RvD1 increased in macrophages of most patients with MCI and pre-MCI. The cognitive status of patients with MCI and pre-MCI appeared overall stabilized because MMSE scores at the first (25.9), second (26.9), and third visit (25.7) were not significantly different. However, the MMSE responses were individual and fluctuating suggesting the effect of morbidities and other events on cognition. One patient with MCI achieved cognitive stabilization for 15 months on v-3 supplementation supported by daily bicycle exercise. Three patients with ApoE4/ApoE3 MCI have shown no improvement and progressive MMSE decline. In agreement with previous studies, progression of AD was not changed by supplementation in patients with MMSE ,19. We speculate that an important mechanism of v-3 on Ab phagocytosis is related to an increase in SPMs, such as RvD1, which improved Ab phagocytosis by AD macrophages in vitro (4). However, in patient #10, significant discrepancy between MFI and RvD1 was observed. The supplementation with v-3 fatty acids has therapeutic effects in chronic inflammatory and metabolic diseases (17) , related in part to the SPM's resolvins, protectins, and maresins, which resolve inflammation, protect organs, and stimulate tissue regeneration (18) . v-3 Supplementation has been shown to protect against mortality related to myocardial infarction and stroke. However, conflicting results have also been reported, which could relate to genetic factors controlling the processing of dietary lipids (17) . Epidemiologic studies showed cognitive benefits against dementia with fish consumption (19) and v-3 supplementation (20) , especially in the ApoE4-negative subgroup (21) . A double-blind, controlled study of DHA (2 g) over 18 mo in 295 participants with MMSE 14-26 was not effective in the total sample except in a subgroup of ApoE4-negative patients (22) . In an v-3 study of 174 patients with MMSE .15, no effect was observed in the total population, but significant slowing of MMSE decline was observed in the subgroup with MMSE .27 (23) . A randomized study of v-3 supplementation in patients with AD showed positive MMSE results over 12 months (24) .
In conclusion, this pilot study shows that the supplementation of patients with MCI by v-3 and antioxidants improves anti-Ab immunity possibly related to production of SPMs by macrophages. In addition, the result suggests cognitive stabilization in comparison to historical controls (23) . The effects of v-3 on immunity and cognition should be tested in a clinical trial. 
